TY - JOUR

T1 - Симпатоадреналовая активность и сон ' поиск маркера гиперактивации при инсомнии

AU - Bochkarev, Mikhail V.

AU - Kulakova, Maria A.

AU - Kemstach, Valeria V.

AU - Gordeev, Aleksey D.

AU - Zabroda, Ekaterina A.

AU - Osipenko, Sofia I.

AU - Shashkova, Tatyana V.

AU - Korostovtseva, Lyudmila S.

AU - Sviryaev, Yuri V.

N1 - Funding Information: Исследование выполнено при поддержке гранта РФФИ № 20–013–00874. / The study was supported by the RFBR grant № 20– 013–00874. Publisher Copyright: © 2021 All-Russian Public Organization Antihypertensive League. All rights reserved.

PY - 2021

Y1 - 2021

N2 - Objective. To assess subjective and objective sleep characteristics and urinary metanephrine levels in patients with insomnia. Design and methods. We included patients with insomnia complaints and those without sleep-related complaints (control group) 18-75 years old. Subjective evaluation of the main sleep characteristics during the last month was assessed by the Pittsburgh Sleep Quality questionnaire, daytime sleepiness ' by the Epworth Sleepiness Scale. For objective sleep evaluation we performed one-night polysomnography (PSG). Within 1 week after the PSG, daily urine was collected to determine the level of metaepinephrine. Results. The groups did not differ by age, mean sleep duration over the past month, number of night awakenings by the Pittsburgh Questionnaire, and level of daytime sleepiness. Sleep latency in insomnia group was 15 minutes longer than in the control group. PSG showed higher apnea-hypopnea and desaturation indices in the control group. There were no differences in daily urinary metanephrine excretion in the main and control groups. Correlation analysis showed no significant association between the metanephrine levels and the severity of somnolence and the index of periodic limb movements. Conclusions. Our analysis showed no significant differences in the daily urine metanephrine levels and the main PSG sleep characteristics among subjects with and without insomnia. Further work is required to clarify markers of insomnia and their negative health effects.

AB - Objective. To assess subjective and objective sleep characteristics and urinary metanephrine levels in patients with insomnia. Design and methods. We included patients with insomnia complaints and those without sleep-related complaints (control group) 18-75 years old. Subjective evaluation of the main sleep characteristics during the last month was assessed by the Pittsburgh Sleep Quality questionnaire, daytime sleepiness ' by the Epworth Sleepiness Scale. For objective sleep evaluation we performed one-night polysomnography (PSG). Within 1 week after the PSG, daily urine was collected to determine the level of metaepinephrine. Results. The groups did not differ by age, mean sleep duration over the past month, number of night awakenings by the Pittsburgh Questionnaire, and level of daytime sleepiness. Sleep latency in insomnia group was 15 minutes longer than in the control group. PSG showed higher apnea-hypopnea and desaturation indices in the control group. There were no differences in daily urinary metanephrine excretion in the main and control groups. Correlation analysis showed no significant association between the metanephrine levels and the severity of somnolence and the index of periodic limb movements. Conclusions. Our analysis showed no significant differences in the daily urine metanephrine levels and the main PSG sleep characteristics among subjects with and without insomnia. Further work is required to clarify markers of insomnia and their negative health effects.

KW - Insomnia

KW - Metanephrine

KW - Pittsburgh questionnaire

KW - Polysomnography

KW - Sleep disorders

UR - http://www.scopus.com/inward/record.url?scp=85123885701&partnerID=8YFLogxK

U2 - 10.18705/1607-419X-2021-27-5-546-552

DO - 10.18705/1607-419X-2021-27-5-546-552

M3 - статья

AN - SCOPUS:85123885701

VL - 27

SP - 546

EP - 552

JO - Arterial Hypertension (Russian Federation)

JF - Arterial Hypertension (Russian Federation)

SN - 1607-419X

IS - 5

ER -